Date | Price Target | Rating | Analyst |
---|---|---|---|
7/2/2024 | Buy | TD Cowen | |
7/2/2024 | $35.00 | Buy | Jefferies |
7/2/2024 | $35.00 | Buy | Stifel |
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
10-Q - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
8-K - Rapport Therapeutics, Inc. (0002012593) (Filer)
TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy
Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
Stifel initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
TD Cowen analyst Joseph Thome initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating.
Jefferies analyst Andrew Tsai initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.
Stifel analyst Paul Matteis initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $35.
BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced presentations at two upcoming medical conferences: the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress (EEC) in Rome, Italy, September 7-11, 2024, and the 2024 Epilepsy Foundation Pipeline Conference in Atlanta, Ga., September 25-26, 2024. At EEC, Rapport will present on the novel design of a Phase 2a proof-of-concept trial for the company's lead product
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences: The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET. Interested parties may access a live and archived webcast of the Morgan Stanley
- Strengthened Board and management with appointments of experienced biotech leaders Troy Ignelzi, Sarah Boyce, John Healy and Kristina Haeckl - - Strong cash position of $219 million at the end of Q2 will support multiple clinical readouts - Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "Our tea